Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;59(2):753-762.
doi: 10.3233/JAD-170399.

Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease

Federica Cacciamani  1 , Caroline Tandetnik  1   2 , Geoffroy Gagliardi  1 , Hugo Bertin  3   4 , Marie-Odile Habert  3   4 , Harald Hampel  1   5   6   7 , Laurie Boukadida  1 , Marie Révillon  1 , Stéphane Epelbaum  1   5   7 , Bruno Dubois  1   5   7 ; INSIGHT-PreAD study group
Collaborators, Affiliations
Free article

Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease

Federica Cacciamani et al. J Alzheimers Dis. 2017.
Free article

Abstract

Background: Subjective cognitive decline (SCD) may result from many conditions, including Alzheimer's disease (AD).

Objective: In this study, we searched for a specific pattern of SCD in asymptomatic individuals at risk for AD.

Methods: Cognitively normal older adults (N = 318) reporting SCD and their informants were enrolled in the INSIGHT-PreAD cohort. We examined the relationship between six SCD measures and both cognitive scores and AD neuroimaging markers (amyloid burden, hippocampal atrophy and brain hypometabolism). An awareness of cognitive decline index (ACDI) has been introduced based on the subject-informant discrepancy in a questionnaire of SCD and participants with low versus high awareness were compared.

Results: Scores in the INSIGHT-PreAD SCD questionnaires did not correlate with AD neuroimaging markers. As well, no correlation has been found between SCD measures and cognitive scores. Comparing subjects with a low (n = 19) and high (n = 86) level of awareness, no significant difference in terms of demography, neuropsychiatric symptoms, autonomy, quality of life, cognition, and hippocampal volume was found. However, the "low awareness" group showed greater amyloid burden and lower cortical metabolism, compared to the "high awareness" group.

Conclusion: This study provided additional evidence that reporting SCD by itself is not a specific symptom of preclinical AD. Conversely, a low cognitive awareness (namely, when subjects report fewer difficulties than their relatives do) may represent a very early form of anosognosia and serve as a specific indicator of preclinical AD. This finding is of key importance as an enrichment factor to consider in both clinical practice and research trials.

Keywords: Alzheimer’s disease; awareness; biomarkers; cognitive complaints; subjective cognitive decline.

PubMed Disclaimer

MeSH terms